Showing results (2101-2110 of 2,136) with videos related to
Sort By:
Pageof 214
Journal of the American Academy of Dermatology|February 8, 2019
Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICTNicholas J Taylor, Nandita Mitra, Lu Qian, et al.Nature Genetics|May 20, 2008
Common sequence variants on 20q11.22 confer melanoma susceptibilityKevin M Brown, Stuart Macgregor, Grant W Montgomery, et al.Journal of the National Cancer Institute|September 30, 2010
Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL studyF Demenais, H Mohamdi, V Chaudru, et al.Cancer Research|October 19, 2006
High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMELAlisa M Goldstein, May Chan, Mark Harland, et al.Nature Genetics|November 5, 2003
Heterozygous mutations of the kinesin KIF21A in congenital fibrosis of the extraocular muscles type 1 (CFEOM1)Koki Yamada, Caroline Andrews, Wai-Man Chan, et al.International Journal of Cancer|August 1, 2014
Fine mapping of genetic susceptibility loci for melanoma reveals a mixture of single variant and multiple variant regionsJennifer H Barrett, John C Taylor, Chloe Bright, et al.The Journal of Investigative Dermatology|August 24, 2017
Germline Variation at CDKN2A and Associations with Nevus Phenotypes among Members of Melanoma FamiliesNicholas J Taylor, Nandita Mitra, Alisa M Goldstein, et al.Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 15, 2021
Germline ATM variants predispose to melanoma: a joint analysis across the GenoMEL and MelaNostrum consortiaB Dalmasso, L Pastorino, V Nathan, et al.JNCI Cancer Spectrum|July 26, 2021
Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in the Childhood Cancer Survivor StudyJung Kim, Matthew Gianferante, Danielle M Karyadi, et al.Journal of Medicinal Chemistry|May 26, 2012
Discovery of novel PI3-kinase δ specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibitionBrian S Safina, Stewart Baker, Matt Baumgardner, et al.Pageof 214